TCRT · Alaunos Therapeutics, Inc. · Executive Compensation
$1.49
-0.02 (-1.32%)
At close · Sep 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements which raises substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$3.84M
Shares
2.54M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Melinda Lackey | Legal & Administration, Corporate Secretary | $430,370 |
| Kevin Boyle | Former Chief Executive Officer | $392,500 |
| Dale Curtis Hogue | Interim Chief Executive Officer | $308,344 |
| Ferdinand Groenewald | Vice President, Finance | $162,304 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Melinda Lackey | SVP, Legal & Administration | $701,737 |
| Drew Deniger | VP, Research and Development | $629,680 |
| Dale Curtis Hogue | Interim Chief Executive Officer | $48,153 |
| Ferdinand Groenewald | Vice President, Finance | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Kevin Boyle | Chief Executive Officer | $1,792,818 |
| Drew Deniger | VP, Research and Development | $949,113 |
| Melinda Lackey | SVP, Legal & Administration | $764,743 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kevin Boyle | Chief Executive Officer | $4,573,753 |
| Heidi Hagen | Former Interim Chief Executive Officer | $2,730,871 |
| Eleanor de Groot | EVP, Operations | $2,174,017 |
| Jill Buck | — | $1,873,742 |
| Laurence James Neil Cooper | Former Chief Executive Officer | $1,531,130 |
| Raffaele Baffa | Chief Medical Officer | $1,034,270 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Laurence James Neil Cooper | Former Chief Executive Officer | $3,007,922 |
| Raffaele Baffa | Chief Medical Officer | $1,673,584 |
| Satyavrat Shukla | Former Chief Financial Officer | $1,252,211 |
| Robert Hadfield | Chief Legal Officer and Secretary | $1,006,811 |
| Eleanor de Groot | EVP, Operations | $935,112 |
| Heidi Hagen | Former Interim Chief Executive Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Laurence James Neil Cooper | Former Chief Executive Officer | $3,317,574 |
| Satyavrat Shukla | Former Chief Financial Officer | $1,822,218 |
| David Mauney | President | $1,448,931 |
| Robert Hadfield | Chief Legal Officer and Secretary | $1,081,822 |
| Kevin G. Lafond | Sr. Vice President – Finance, Chief Accounting Officer and Treasurer | $843,123 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Laurence James Neil Cooper | Former Chief Executive Officer | $1,589,239 |
| Robert Hadfield | Chief Legal Officer and Secretary | $836,091 |
| David Mauney | President | $608,756 |
| Kevin G. Lafond | Sr. Vice President – Finance, Chief Accounting Officer and Treasurer | $398,998 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Laurence James Neil Cooper | M.D., Ph.D. Chief Executive Officer | $2,894,244 |
| David Mauney | President | $2,297,974 |
| Kevin G. Lafond | Sr. Vice President – Finance, Chief Accounting Officer and Treasurer | $581,224 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Melinda Lackey | Legal and Administrative Officer | Resigned | 2025-07-22 |
| Holger Weis | Chief Executive Officer | Appointed | 2025-07-17 |
| Dale Curtis Hogue | director | Resigned | 2025-07-17 |
| Michael A. Jerman | director | Appointed | 2025-07-17 |
| Dale Curtis Hogue, Jr. | Director | Resigned | 2025-07-02 |
| Holger Weis | Chief Executive Officer | Appointed | 2025-07-02 |
| Dale Curtis Hogue, Jr. | Chief Executive Officer | Resigned | 2025-07-02 |
| Robert Hofmeister, Ph.D. | member of the board of directors | Resigned | 2025-04-18 |